NEUROTRANSMITTERS, also known as CHEMICAL MESSENGERS, are endogenous chemicals that enable neurotransmission . They transmit signals across a chemical synapse , such as a neuromuscular junction , from one neuron (nerve cell) to another "target" neuron, muscle cell , or gland cell . Neurotransmitters are released from synaptic vesicles in synapses into the synaptic cleft , where they are received by receptors on the target cells. Many neurotransmitters are synthesized from simple and plentiful precursors such as amino acids , which are readily available from the diet and only require a small number of biosynthetic steps for conversion. Neurotransmitters play a major role in shaping everyday life and functions. Their exact numbers are unknown, but more than 100 chemical messengers have been uniquely identified.
* 1 Mechanism * 2 Discovery * 3 Identification
* 4 Types
* 4.1 List of neurotransmitters, peptides, and gasotransmitters
* 5 Actions
* 5.1 Excitatory and inhibitory * 5.2 Examples of important neurotransmitter actions
* 6 Brain neurotransmitter systems
* 7 Drug effects
* 7.1 Agonists
* 7.2 Antagonists
* 7.2.1 Drug antagonists
* 7.3 Precursors
* 8 Diseases and disorders
Neurotransmitters are stored in a synapse in synaptic vesicles , clustered beneath the membrane in the axon terminal located at the presynaptic side of the synapse. Neurotransmitters are released into and diffused across the synaptic cleft , where they bind to specific receptors in the membrane on the postsynaptic side of the synapse.
Most neurotransmitters are about the size of a single amino acid, however, some neurotransmitters may be the size of larger proteins or peptides . A released neurotransmitter is typically available in the synaptic cleft for a short time before it is metabolized by enzymes, pulled back into the presynaptic neuron through reuptake , or bound to a postsynaptic receptor . Nevertheless, short-term exposure of the receptor to a neurotransmitter is typically sufficient for causing a postsynaptic response by way of synaptic transmission .
In response to a threshold action potential or graded electrical potential , a neurotransmitter is released at the presynaptic terminal. Low level "baseline" release also occurs without electrical stimulation. The released neurotransmitter may then move across the synapse to be detected by and bind with receptors in the postsynaptic neuron. Binding of neurotransmitters may influence the postsynaptic neuron in either an inhibitory or excitatory way. This neuron may be connected to many more neurons, and if the total of excitatory influences are greater than those of inhibitory influences, the neuron will also "fire". Ultimately it will create a new action potential at its axon hillock to release neurotransmitters and pass on the information to yet another neighboring neuron.
Until the early 20th century, scientists assumed that the majority of synaptic communication in the brain was electrical. However, through the careful histological examinations by Ramón y Cajal (1852–1934), a 20 to 40 nm gap between neurons, known today as the synaptic cleft , was discovered. The presence of such a gap suggested communication via chemical messengers traversing the synaptic cleft, and in 1921 German pharmacologist Otto Loewi (1873–1961) confirmed that neurons can communicate by releasing chemicals. Through a series of experiments involving the vagus nerves of frogs, Loewi was able to manually slow the heart rate of frogs by controlling the amount of saline solution present around the vagus nerve. Upon completion of this experiment, Loewi asserted that sympathetic regulation of cardiac function can be mediated through changes in chemical concentrations. Furthermore, Otto Loewi is credited with discovering acetylcholine (ACh)—the first known neurotransmitter. Some neurons do, however, communicate via electrical synapses through the use of gap junctions , which allow specific ions to pass directly from one cell to another.
There are four main criteria for identifying neurotransmitters:
* The chemical must be synthesized in the neuron or otherwise be present in it. * When the neuron is active, the chemical must be released and produce a response in some target. * The same response must be obtained when the chemical is experimentally placed on the target. * A mechanism must exist for removing the chemical from its site of activation after its work is done.
However, given advances in pharmacology, genetics, and chemical neuroanatomy , the term "neurotransmitter" can be applied to chemicals that:
* Carry messages between neurons via influence on the postsynaptic membrane. * Have little or no effect on membrane voltage, but have a common carrying function such as changing the structure of the synapse. * Communicate by sending reverse-direction messages that affect the release or reuptake of transmitters.
The anatomical localization of neurotransmitters is typically determined using immunocytochemical techniques, which identify either the location of either the transmitter substances themselves, or of the enzymes that are involved in their synthesis. Immunocytochemical techniques have also revealed that many transmitters, particularly the neuropeptides, are co-localized, that is, one neuron may release more than one transmitter from its synaptic terminal. Various techniques and experiments such as staining, stimulating, and collecting can be used to identify neurotransmitters throughout the central nervous system .
There are many different ways to classify neurotransmitters. Dividing them into amino acids , peptides , and monoamines is sufficient for some classification purposes.
* AMINO ACIDS : glutamate , aspartate , D-serine , γ-aminobutyric acid (GABA), glycine * GASOTRANSMITTERS : nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H2S) * MONOAMINES : dopamine (DA), norepinephrine (noradrenaline; NE, NA), epinephrine (adrenaline), histamine , serotonin (SER, 5-HT) * TRACE AMINES : phenethylamine , N-methylphenethylamine , tyramine , 3-iodothyronamine , octopamine , tryptamine , etc. * PEPTIDES : somatostatin , substance P , cocaine and amphetamine regulated transcript , opioid peptides * PURINES : adenosine triphosphate (ATP), adenosine * Others: acetylcholine (ACh), anandamide , etc.
In addition, over 50 neuroactive peptides have been found, and new ones are discovered regularly. Many of these are "co-released" along with a small-molecule transmitter. Nevertheless, in some cases a peptide is the primary transmitter at a synapse. β-endorphin is a relatively well-known example of a peptide neurotransmitter because it engages in highly specific interactions with opioid receptors in the central nervous system .
Single ions (such as synaptically released zinc ) are also considered neurotransmitters by some, as well as some gaseous molecules such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S). The gases are produced in the neural cytoplasm and are immediately diffused through the cell membrane into the extracellular fluid and into nearby cells to stimulate production of second messengers. Soluble gas neurotransmitters are difficult to study, as they act rapidly and are immediately broken down, existing for only a few seconds.
The most prevalent transmitter is glutamate , which is excitatory at well over 90% of the synapses in the human brain. The next most prevalent is Gamma-Aminobutyric Acid, or GABA, which is inhibitory at more than 90% of the synapses that do not use glutamate. Although other transmitters are used in fewer synapses, they may be very important functionally: the great majority of psychoactive drugs exert their effects by altering the actions of some neurotransmitter systems, often acting through transmitters other than glutamate or GABA. Addictive drugs such as cocaine and amphetamines exert their effects primarily on the dopamine system. The addictive opiate drugs exert their effects primarily as functional analogs of opioid peptides , which, in turn, regulate dopamine levels.
LIST OF NEUROTRANSMITTERS, PEPTIDES, AND GASOTRANSMITTERS
This list is incomplete ; you can help by expanding it .
CATEGORY NAME ABBREVIATION METABOTROPIC IONOTROPIC
α2-Adrenergic receptors , imidazoline receptors NMDA receptors
Small: Amino acids Asparagine Asp – NMDA receptors
Small: Amino acids Gamma-aminobutyric acid GABA GABAB receptors GABAA receptors , GABAA-ρ receptors
Small: Amino acids
Small: Amino acids D-serine Ser – NMDA receptors
h TAAR1 , various serotonin receptors –
Lipid Anandamide AEA Cannabinoid receptors –
Lipid 2-Arachidonoylglycerol 2-AG Cannabinoid receptors –
Lipid 2-Arachidonyl glyceryl ether 2-AGE Cannabinoid receptors –
Cannabinoid receptors –
Small: Purine Adenosine triphosphate ATP P2Y receptors P2X receptors
PP : Galanins Galanin
PP: Galanins Galanin-like peptide
PP: Gastrins Gastrin
PP: Neurohypophyseals Neurophysin I
PP: Neurohypophyseals Neurophysin II
PP: Opioids Enkephalin
δ- Opioid receptor –
PP: Opioids Dynorphin
κ- Opioid receptor –
PP: Opioids Endorphin
μ- Opioid receptors –
PP: Opioids Endomorphin
μ- Opioid receptors –
PP: Secretins Secretin
Secretin receptor –
PP: Secretins Motilin
Motilin receptor –
PP: Somatostatins Somatostatin
Somatostatin receptors –
PP: Tachykinins Neurokinin B
PP: Tachykinins Substance P
PP: Tachykinins Neuropeptide K
PP: Other Cocaine- and amphetamine-regulated transcript CART Unknown Gi/Go -coupled receptor –
PP: Other Bombesin
PP: Other Gastrin releasing peptide GRP – –
PP: Other Kisspeptin
Gasotransmitter Hydrogen sulfide H2S – –
Neurons form elaborate networks through which nerve impulses—action potentials —travel. Each neuron has as many as 15,000 connections with neighboring neurons.
Neurons do not touch each other (except in the case of an electrical synapse through a gap junction); instead, neurons interact at contact points called synapses: a junction within two nerve cells, consisting of a miniature gap which impulses pass by a neurotransmitter. A neuron transports its information by way of a nerve impulse called an action potential. When an action potential arrives at the synapse's presynaptic terminal button, it may stimulate the release of neurotransmitters. These neurotransmitters are released into the synaptic cleft to bind onto the receptors of the postsynaptic membrane and influence another cell, either in an inhibitory or excitatory way. The next neuron may be connected to many more neurons, and if the total of excitatory influences minus inhibitory influences is great enough, it will also "fire". That is to say, it will create a new action potential at its axon hillock, releasing neurotransmitters and passing on the information to yet another neighboring neuron.
EXCITATORY AND INHIBITORY
A neurotransmitter can influence the function of a neuron through a remarkable number of mechanisms. In its direct actions in influencing a neuron’s electrical excitability , however, a neurotransmitter acts in only one of two ways: excitatory or inhibitory. A neurotransmitter influences trans-membrane ion flow either to increase (excitatory) or to decrease (inhibitory) the probability that the cell with which it comes in contact will produce an action potential. Thus, despite the wide variety of synapses, they all convey messages of only these two types, and they are labeled as such. Type I synapses are excitatory in their actions, whereas type II synapses are inhibitory . Each type has a different appearance and is located on different parts of the neurons under its influence. Each neuron receives thousands of excitatory and inhibitory signals every second.
Type I (excitatory) synapses are typically located on the shafts or the spines of dendrites, whereas type II (inhibitory) synapses are typically located on a cell body. In addition, Type I synapses have round synaptic vesicles, whereas the vesicles of type II synapses are flattened. The material on the presynaptic and post-synaptic membranes is denser in a Type I synapse than it is in a type II, and the type I synaptic cleft is wider. Finally, the active zone on a Type I synapse is larger than that on a Type II synapse.
The different locations of type I and type II synapses divide a neuron into two zones: an excitatory dendritic tree and an inhibitory cell body. From an inhibitory perspective, excitation comes in over the dendrites and spreads to the axon hillock to trigger an action potential . If the message is to be stopped, it is best stopped by applying inhibition on the cell body, close to the axon hillock where the action potential originates. Another way to conceptualize excitatory–inhibitory interaction is to picture excitation overcoming inhibition. If the cell body is normally in an inhibited state, the only way to generate an action potential at the axon hillock is to reduce the cell body’s inhibition. In this "open the gates" strategy, the excitatory message is like a racehorse ready to run down the track, but first the inhibitory starting gate must be removed.
EXAMPLES OF IMPORTANT NEUROTRANSMITTER ACTIONS
As explained above, the only direct action of a neurotransmitter is to activate a receptor. Therefore, the effects of a neurotransmitter system depend on the connections of the neurons that use the transmitter, and the chemical properties of the receptors that the transmitter binds to.
Here are a few examples of important neurotransmitter actions:
BRAIN NEUROTRANSMITTER SYSTEMS
Neurons expressing certain types of neurotransmitters sometimes form distinct systems, where activation of the system affects large volumes of the brain, called volume transmission . Major neurotransmitter systems include the noradrenaline (norepinephrine) system, the dopamine system, the serotonin system, and the cholinergic system, among others. It should be noted that trace amines , primarily via TAAR1 activation, have a very significant effect on neurotransmission in monoamine pathways (i.e., dopamine, histamine, norepinephrine, and serotonin pathways) throughout the brain. A brief comparison of these systems follows:
Noradrenaline system NORADRENERGIC PATHWAYS:
* Locus coeruleus (LC) projections
* LC →
* Lateral tegmental field (LTF) projections
* anxiety * arousal (wakefulness and attention) * circadian rhythm * cognitive control and working memory (co-regulated by dopamine) * hunger * medullary control of respiration * negative emotional memory * reward perception (minor role)
Dopamine system DOPAMINERGIC PATHWAYS :
* Ventral tegmental area (VTA) projections
* VTA →
* aversion * cognitive control and working memory (co-regulated by norepinephrine) * mood * reward perception (primary mediator) * positive reinforcement * motivation (incentive salience ) * motor system function * sexual arousal , orgasm , and refractory period (via neuroendocrine regulation)
* Tuberomammillary nucleus (TMN) projections
* arousal (wakefulness and attention) * feeding and energy balance * learning * memory * sleep
* Caudal projections
* Rostral projections
* appetite satiety * arousal (wakefulness and attention) * body temperature regulation * emotion and mood , potentially including aggression * reward perception (minor role) * sensory perception * sleep
Forebrain cholinergic nuclei (FCN): Nucleus basalis of Meynert , medial septal nucleus , and diagonal band
* Forebrain nuclei projections
Brainstem cholinergic nuclei (BCN): Pedunculopontine nucleus , laterodorsal tegmentum , medial habenula , and parabigeminal nucleus
* Brainstem nuclei projections
* arousal (wakefulness and attention) * emotion * learning * motor system function * short-term memory * reward perception (minor role)
Understanding the effects of drugs on neurotransmitters comprises a significant portion of research initiatives in the field of neuroscience . Most neuroscientists involved in this field of research believe that such efforts may further advance our understanding of the circuits responsible for various neurological diseases and disorders, as well as ways to effectively treat and someday possibly prevent or cure such illnesses.
Drugs can influence behavior by altering neurotransmitter activity. For instance, drugs can decrease the rate of synthesis of neurotransmitters by affecting the synthetic enzyme(s) for that neurotransmitter. When neurotransmitter syntheses are blocked, the amount of neurotransmitters available for release becomes substantially lower, resulting in a decrease in neurotransmitter activity. Some drugs block or stimulate the release of specific neurotransmitters. Alternatively, drugs can prevent neurotransmitter storage in synaptic vesicles by causing the synaptic vesicle membranes to leak. Drugs that prevent a neurotransmitter from binding to its receptor are called receptor antagonists . For example, drugs used to treat patients with schizophrenia such as haloperidol, chlorpromazine, and clozapine are antagonists at receptors in the brain for dopamine. Other drugs act by binding to a receptor and mimicking the normal neurotransmitter. Such drugs are called receptor agonists . An example of a receptor agonist is Valium, a benzodiazepine that mimics effects of the endogenous neurotransmitter gamma-aminobutyric acid (GABA) to decrease anxiety. Other drugs interfere with the deactivation of a neurotransmitter after it has been released, thereby prolonging the action of a neurotransmitter. This can be accomplished by blocking re-uptake or inhibiting degradative enzymes. Lastly, drugs can also prevent an action potential from occurring, blocking neuronal activity throughout the central and peripheral nervous system . Drugs such as tetrodotoxin that block neural activity are typically lethal.
Drugs targeting the neurotransmitter of major systems affect the
whole system, which can explain the complexity of action of some
Cocaine , for example, blocks the re-uptake of dopamine back
into the presynaptic neuron, leaving the neurotransmitter molecules in
the synaptic gap for an extended period of time. Since the dopamine
remains in the synapse longer, the neurotransmitter continues to bind
to the receptors on the postsynaptic neuron, eliciting a pleasurable
emotional response. Physical addiction to cocaine may result from
prolonged exposure to excess dopamine in the synapses, which leads to
the downregulation of some post-synaptic receptors. After the effects
of the drug wear off, an individual can become depressed due to
decreased probability of the neurotransmitter binding to a receptor.
Fluoxetine is a selective serotonin re-uptake inhibitor (SSRI), which
blocks re-uptake of serotonin by the presynaptic cell which increases
the amount of serotonin present at the synapse and furthermore allows
it to remain there longer, providing potential for the effect of
naturally released serotonin.
Main article: Agonist
THIS SECTION NEEDS EXPANSION with: coverage of full agonists and their distinction from partial agonist and inverse agonist.. You can help by adding to it . (August 2015)
An agonist is a chemical capable of binding to a receptor, such as a neurotransmitter receptor, and initiating the same reaction typically produced by the binding of the endogenous substance. An agonist of a neurotransmitter will thus initiate the same receptor response as the transmitter. In neurons, an agonist drug may activate neurotransmitter receptors either directly or indirectly. Direct-binding agonists can be further characterized as full agonists , partial agonists , inverse agonists .
Direct agonists act similar to a neurotransmitter by binding directly
to its associated receptor site(s), which may be located on the
presynaptic neuron or postsynaptic neuron, or both. Typically,
neurotransmitter receptors are located on the postsynaptic neuron,
while neurotransmitter autoreceptors are located on the presynaptic
neuron, as is the case for monoamine neurotransmitters ; in some
cases, a neurotransmitter utilizes retrograde neurotransmission , a
type of feedback signaling in neurons where the neurotransmitter is
released postsynaptically and binds to target receptors located on the
Indirect agonists increase the binding of neurotransmitters at their
target receptors by stimulating the release or preventing the reuptake
of neurotransmitters. Some indirect agonists trigger neurotransmitter
release and prevent neurotransmitter reuptake .
Main article: Receptor antagonist
An antagonist is a chemical that acts within the body to reduce the physiological activity of another chemical substance (as an opiate); especially one that opposes the action on the nervous system of a drug or a substance occurring naturally in the body by combining with and blocking its nervous receptor.
There are two main types of antagonist: direct-acting Antagonist and indirect-acting Antagonists:
* Direct-acting antagonist- which takes up space present on receptors which are otherwise taken up by neurotransmitters themselves. This results in neurotransmitters being blocked from binding to the receptors. The most common is called Atropine. * Indirect-acting antagonist- drugs that inhibit the release/production of neurotransmitters (e.g., Reserpine ).
An antagonist drug is one that attaches (or binds) to a site called a receptor without activating that receptor to produce a biological response. It is therefore said to have no intrinsic activity. An antagonist may also be called a receptor "blocker" because they block the effect of an agonist at the site. The pharmacological effects of an antagonist therefore result in preventing the corresponding receptor site's agonists (e.g., drugs, hormones, neurotransmitters) from binding to and activating it. Antagonists may be "competitive" or "irreversible".
A competitive antagonist competes with an agonist for binding to the receptor. As the concentration of antagonist increases, the binding of the agonist is progressively inhibited, resulting in a decrease in the physiological response. High concentration of an antagonist can completely inhibit the response. This inhibition can be reversed, however, by an increase of the concentration of the agonist, since the agonist and antagonist compete for binding to the receptor. Competitive antagonists, therefore, can be characterized as shifting the dose-response relationship for the agonist to the right. In the presence of a competitive antagonist, it takes an increased concentration of the agonist to produce the same response observed in the absence of the antagonist.
An irreversible antagonist binds so strongly to the receptor as to render the receptor unavailable for binding to the agonist. Irreversible antagonists may even form covalent chemical bonds with the receptor. In either case, if the concentration of the irreversible antagonist is high enough, the number of unbound receptors remaining for agonist binding may be so low that even high concentrations of the agonist do not produce the maximum biological response.
Biosynthetic pathways for catecholamines and trace amines in the
human brain L-
While intake of neurotransmitter precursors does increase neurotransmitter synthesis, evidence is mixed as to whether neurotransmitter release and postsynaptic receptor firing is increased. Even with increased neurotransmitter release, it is unclear whether this will result in a long-term increase in neurotransmitter signal strength, since the nervous system can adapt to changes such as increased neurotransmitter synthesis and may therefore maintain constant firing. Some neurotransmitters may have a role in depression and there is some evidence to suggest that intake of precursors of these neurotransmitters may be useful in the treatment of mild and moderate depression.
Administration of L-tryptophan , a precursor for serotonin , is seen to double the production of serotonin in the brain. It is significantly more effective than a placebo in the treatment of mild and moderate depression. This conversion requires vitamin C . 5-hydroxytryptophan (5-HTP), also a precursor for serotonin , is more effective than a placebo.
DISEASES AND DISORDERS
Diseases and disorders may also affect specific neurotransmitter
systems. For example, problems in producing dopamine can result in
Parkinson\'s disease , a disorder that affects a person's ability to
move as they want to, resulting in stiffness, tremors or shaking, and
other symptoms. Some studies suggest that having too little or too
much dopamine or problems using dopamine in the thinking and feeling
regions of the brain may play a role in disorders like schizophrenia
or attention deficit hyperactivity disorder (ADHD). Similarly, after
some research suggested that drugs that block the recycling, or
reuptake, of serotonin seemed to help some people diagnosed with
depression, it was theorized that people with depression might have
lower-than-normal serotonin levels. Though widely popularized, this
theory was not borne out in subsequent research. Furthermore,
problems with producing or using glutamate have been suggestively and
tentatively linked to many mental disorders, including autism ,
obsessive compulsive disorder (OCD), schizophrenia , and depression .
CAPON Binds Nitric Oxide Synthase, Regulating NMDA
Generally, there are no scientifically established "norms" for appropriate levels or "balances" of different neurotransmitters. It is in most cases pragmatically impossible to even measure levels of neurotransmitters in a brain or body at any distinct moments in time. Neurotransmitters regulate each other's release, and weak consistent imbalances in this mutual regulation were linked to temperament in healthy people . Strong imbalances or disruptions to neurotransmitter systems have been associated with many diseases and mental disorders. These include Parkinson's, depression, insomnia, Attention Deficit Hyperactivity Disorder (ADHD), anxiety, memory loss, dramatic changes in weight and addictions. Chronic physical or emotional stress can be a contributor to neurotransmitter system changes. Genetics also plays a role in neurotransmitter activities. Apart from recreational use, medications that directly and indirectly interact one or more transmitter or its receptor are commonly prescribed for psychiatric and psychological issues. Notably, drugs interacting with serotonin and norepinephrine are prescribed to patients with problems such as depression and anxiety—though the notion that there is much solid medical evidence to support such interventions has been widely criticized.
ELIMINATION OF NEUROTRANSMITTERS
A neurotransmitter must be broken down once it reaches the post-synaptic cell to prevent further excitatory or inhibitory signal transduction. This allows new signals to be produced from the adjacent nerve cells. When the neurotransmitter has been secreted into the synaptic cleft, it binds to specific receptors on the postsynaptic cell, thereby generating a postsynaptic electrical signal. The transmitter must then be removed rapidly to enable the postsynaptic cell to engage in another cycle of neurotransmitter release, binding, and signal generation. Neurotransmitters are terminated in three different ways:
For example, choline is taken up and recycled by the pre-synaptic neuron to synthesize more ACh. Other neurotransmitters such as dopamine are able to diffuse away from their targeted synaptic junctions and are eliminated from the body via the kidneys, or destroyed in the liver. Each neurotransmitter has very specific degradation pathways at regulatory points, which may be targeted by the body's regulatory system or by recreational drugs .
* Neurotransmission * Neurotransmitter receptor * Neurotransmitter release * Gasotransmitters * Kiss-and-run fusion * Neuromuscular transmission * Neuropsychopharmacology * Neuroendocrine * Neuroendocrinology * Natural neuroactive substance
* ^ In the central nervous system, anandamide other endocannabinoids utilize retrograde neurotransmission, since their release is postsynaptic, while their target receptor, cannabinoid receptor 1 (CB1), is presynaptic. The cannabis plant contains Δ9-tetrahydrocannabinol , which is a direct agonist at CB1.
* ^ Lodish, H.; Berk, A.; Zipursky, S.L. (2000). Molecular Cell
Biology: Section 21.4Neurotransmitters, Synapses, and Impulse
Transmission (4th ed.). New York: W. H. Freeman.
* ^ Cherry, Kendra. "What is a Neurotransmitter?". Retrieved 6
* ^ Elias, L. J, & Saucier, D. M. (2005). Neuropsychology: Clinical
and Experimental Foundations. Boston: Pearson
* ^ A B C Robert Sapolsky (2005). "Biology and Human Behavior: The
Neurological Origins of Individuality, 2nd edition". The Teaching
Company. see pages 13 & 14 of Guide
* ^ Schacter, Gilbert and Weger. Psychology.United States of
* ^ A B University of Bristol. "Introduction to Serotonin".
Retrieved 15 October 2009.
* ^ A B C D Miller GM (January 2011). "The emerging role of trace
amine-associated receptor 1 in the functional regulation of monoamine
transporters and dopaminergic activity" . J. Neurochem. 116 (2):
164–176. PMC 3005101 . PMID 21073468 . doi
* ^ A B C Eiden LE, Weihe E (January 2011). "VMAT2: a dynamic
regulator of brain monoaminergic neuronal function interacting with
drugs of abuse" . Ann. N. Y. Acad. Sci. 1216: 86–98. PMC 4183197
. PMID 21272013 . doi :10.1111/j.1749-6632.2010.05906.x .
the CNS vesicular transporter for not only the biogenic amines DA, NE,
EPI, 5-HT, and HIS, but likely also for the trace amines TYR, PEA, and
thyronamine (THYR) ... neurons in mammalian CNS would be
identiﬁable as neurons expressing
VMAT2 for storage, and the
biosynthetic enzyme aromatic amino acid decarboxylase (AADC).
* ^ A B C Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 6:
Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin". In
Sydor A, Brown RY. Molecular Neuropharmacology: A Foundation for
* ^ Ikemoto S (2010). "Brain reward circuitry beyond the mesolimbic
dopamine system: a neurobiological theory" . Neurosci Biobehav Rev. 35
(2): 129–50. PMC 2894302 . PMID 20149820 . doi
:10.1016/j.neubiorev.2010.02.001 . Recent studies on intracranial
self-administration of neurochemicals (drugs) found that rats learn to
self-administer various drugs into the mesolimbic dopamine
structures–the posterior ventral tegmental area, medial shell
nucleus accumbens and medial olfactory tubercle. ... In the 1970s it
was recognized that the olfactory tubercle contains a striatal
component, which is filled with GABAergic medium spiny neurons
receiving glutamatergic inputs form cortical regions and dopaminergic
inputs from the VTA and projecting to the ventral pallidum just like
the nucleus accumbens
Figure 3: The ventral striatum and self-administration of amphetamine
* ^ Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 6: Widely
Projecting Systems: Monoamines, Acetylcholine, and Orexin". In Sydor
A, Brown RY. Molecular Neuropharmacology: A Foundation for Clinical
* ^ A B C Flores A, Maldonado R, Berrendero F (2013).
"Cannabinoid-hypocretin cross-talk in the central nervous system: what
we know so far" . Front Neurosci. 7: 256. PMC 3868890 . PMID
24391536 . doi :10.3389/fnins.2013.00256 .
• Figure 1: Schematic of brain CB1 expression and orexinergic
neurons expressing OX1 or OX2
• Figure 2: Synaptic signaling mechanisms in cannabinoid and orexin
systems * ^ A B "Neurotransmitters and Drugs Chart". Ocw.mit.edu.
Retrieved 25 August 2014.
* ^ "Antagonist". Medical definition of Antagonist. Retrieved 5
* ^ Goeders, Nick E. (2001). "Antagonist". Encyclopedia of Drugs,
Alcohol, and Addictive Behavior. Retrieved 2 December 2014.
* ^ Broadley KJ (March 2010). "The vascular effects of trace amines
and amphetamines". Pharmacol. Ther. 125 (3): 363–375. PMID 19948186
. doi :10.1016/j.pharmthera.2009.11.005 .
* ^ Lindemann L, Hoener MC (May 2005). "A renaissance in trace
amines inspired by a novel GPCR family". Trends Pharmacol. Sci. 26
(5): 274–281. PMID 15860375 . doi :10.1016/j.tips.2005.03.007 .
* ^ Wang X, Li J, Dong G, Yue J (February 2014). "The endogenous
substrates of brain CYP2D". Eur. J. Pharmacol. 724: 211–218. PMID
24374199 . doi :10.1016/j.ejphar.2013.12.025 . The highest level of
brain CYP2D activity was found in the substantia nigra ... The in
vitro and in vivo studies have shown the contribution of the
alternative CYP2D-mediated dopamine synthesis to the concentration of
this neurotransmitter although the classic biosynthetic route to
dopamine from tyrosine is active. ...
Tyramine levels are especially
high in the basal ganglia and limbic system, which are thought to be
related to individual behavior and emotion (Yu et al., 2003c). ... Rat
CYP2D isoforms (2D2/2D4/2D18) are less efficient than human
* t * e
* Behavioral genetics
* Affective neuroscience * Behavioral neuroscience * Chronobiology * Molecular cellular cognition * Motor control * Neurolinguistics * Neuropsychology * Sensory neuroscience * Social neuroscience * Systems neuroscience
* Brain–computer interface * Neural development * Neural network (artificial) * Neural network (biological) * Detection theory * Intraoperative neurophysiological monitoring * Neurochip * Neurodegeneration * Neurodevelopmental disorder * Neurodiversity * Neurogenesis * Neuroimaging * Neuroimmune system * Neuromanagement * Neuromodulation * Neuroplasticity * Neurotechnology * Neurotoxin
* BOOK * CATEGORY * COMMONS * PORTAL * WIKIPROJECT
* v * t * e
AMINO ACID -DERIVED
* MAJOR EXCITATORY/INHIBITORY SYSTEMS:
* BIOGENIC AMINES: Monoamines: 6-OHM
* NAS (normelatonin)
* NEUROPEPTIDES: See here instead.
* NEUROSTEROIDS: See here instead.
Carbon monoxide (CO)
Hydrogen sulfide (H2S)
* v * t * e
* GPCR * * Wnt
* TGF beta * MAPK/ERK
* Notch * JAK-STAT * Akt/PKB * Fas apoptosis * Hippo * PI3K/AKT/mTOR pathway * Integrin receptors
* Hormones * Neurotransmitters/Neuropeptides /Neurohormones * Cytokines * Growth factors * Signaling molecules
* Cell surface * Intracellular * Co-receptor
* cAMP-dependent pathway
* Ca2+ signaling
* General * Transcription preinitiation complex * TFIID * TFIIH
* Juxtacrine * Autocrine / Paracrine * Endocrine
* Intracrine action
* Neurocrine signaling
* Neuroendocrine signaling
* Exocrine signalling
* v * t * e